Affiliation:
1. Department of Clinical and Experimental Oncology, Federal University of Sao Paulo (UNIFESP), Sao Paulo 04037-003, Brazil
2. Laboratory of Genomic Integrity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-3371, USA
Abstract
The transcription factor NRF2 is constitutively active in glioblastoma, a highly aggressive brain tumor subtype with poor prognosis. Temozolomide (TMZ) is the primary chemotherapeutic agent for this type of tumor treatment, but resistance to this drug is often observed. This review highlights the research that is demonstrating how NRF2 hyperactivation creates an environment that favors the survival of malignant cells and protects against oxidative stress and TMZ. Mechanistically, NRF2 increases drug detoxification, autophagy, DNA repair, and decreases drug accumulation and apoptotic signaling. Our review also presents potential strategies for targeting NRF2 as an adjuvant therapy to overcome TMZ chemoresistance in glioblastoma. Specific molecular pathways, including MAPKs, GSK3β, βTRCP, PI3K, AKT, and GBP, that modulate NRF2 expression leading to TMZ resistance are discussed, along with the importance of identifying NRF2 modulators to reverse TMZ resistance and develop new therapeutic targets. Despite the significant progress in understanding the role of NRF2 in GBM, there are still unanswered questions regarding its regulation and downstream effects. Future research should focus on elucidating the precise mechanisms by which NRF2 mediates resistance to TMZ, and identifying potential novel targets for therapeutic intervention.
Funder
Fundação de Amparo à Pesquisa do Estado de São Paulo
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference133 articles.
1. Glioblastoma: Overview of Disease and Treatment;Davis;Clin. J. Oncol. Nurs.,2016
2. Cruz, J.V.R., Batista, C., Afonso, B.d.H., Alexandre-Moreira, M.S., Dubois, L.G., Pontes, B., Neto, V.M., and Mendes, F.D.A. (2022). Obstacles to Glioblastoma Treatment Two Decades after Temozolomide. Cancers, 14.
3. Mechanisms of temozolomide resistance in glioblastoma—A comprehensive review;Singh;Cancer Drug Resist.,2020
4. LQB-118 compound inhibits migration and induces cell death in glioblastoma cells;Bernardo;Oncol. Rep.,2019
5. Cancer drug resistance: An evolving paradigm;Holohan;Nat. Rev. Cancer,2013
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献